Skip to main content
OpenTrials
Completed

NCT Number: NCT05604118

Platelet Enzymatically Oxidized Phospholipids (eoxPL) Characterisation in a Healthy Cohort on and Off Aspirin

Healthy volunteers (n = 28) were recruited from the workplace (14 male, 14 female; age range 20-50 years). Ethical approval, which included informed consent, was from Cardiff University, Schools of Medicine and Dentistry Research Ethics Committee (SMREC16/02). Following a 2-week period free from non-steroidal anti-inflammatory drugs (NSAIDs), peripheral blood was obtained and platelets isolated. Participants were commenced on aspirin 75 mg once daily for seven days and then provided a repeat blood sample. Following a 2-month period, participants were invited to repeat samples pre- and post-aspirin, and again a third time 2 months later.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Platelet Dysfunction Due to Aspirin

Age range

20 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sir Geraint Evans Cardiovascular Research Building

Cardiff, CF144XN, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • two-week washout period from any non-steroidal anti-inflammatory drugs (NSAIDs) use.
  • Ability to take aspirin 75 mg once daily for seven days and sampled thereafter, before stopping the aspirin.
  • Willingness to repeat this process after two months and four months of the initial sampling date.

Exclusion criteria

  • Recent NSAID use

Treatment and study plan

Aspirin

Drug

1 week of aspirin supplementation prior to sampling

Primary outcomes

  1. Platelet EoxPL differences in amounts (ng) as measured by liquid chromatography with tandem mass spectrometry

    Time frame: 4 months

    Samples on and off aspirin will be quantified for the 47 most common eoxPL species (as described by Slatter et al, Cell Metabolism 23, 930-944, May 10, 2016) using established liquid chromatography with tandem mass spectrometry (LC-MS/MS). Differences in amounts on and off aspirin will be quantified and tested for statistical significance.

Sponsors and collaborators

Lead sponsor

Cardiff University

Other

Registry information

Important dates

Study start
2016
Primary completion
2018
Study completion
2022
First posted
Nov 3, 2022
Registry last updated
Nov 3, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.